apalutamide   Click here for help

GtoPdb Ligand ID: 9043

Synonyms: ARN-509 | ARN509 | Erleada® | JNJ-56021927
Approved drug
apalutamide is an approved drug (FDA (2018), EMA (2019))
Compound class: Synthetic organic
Comment: Apalutamide is a novel androgen receptor (AR) antagonist (antiandrogen) that is approved as a treatment for castration-resistant prostate cancer (CRPC) [3]. This compound (91) was discovered in a structure/activity relationship-guided medicinal chemistry program designed to identify antiandrogens devoid of agonistic activity in the setting of androgen receptor overexpression [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 121.42
Molecular weight 477.09
XLogP 2.86
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C21CCC2)c1cnc(c(c1)C(F)(F)F)C#N
Isomeric SMILES CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C21CCC2)c1cnc(c(c1)C(F)(F)F)C#N
InChI InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)
No information available.
Summary of Clinical Use Click here for help
Apalutamide (using research codes ARN-509 and JNJ-56021927) was evaluated in several Phase 3 clinical trials in prostate cancer patients. As a result of positive clinical outcomes (see NCT01946204 results in Smith et al. (2018) [4]), the US FDA approved use of apalutamide for the treatment of non-metastatic castration-resistant prostate cancer in February 2018. This approval was expanded in September 2019 to include treatment of metastatic castration-sensitive prostate cancer. Click here to link to ClinicalTrials.gov's complete list of apalutamide trials.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01946204 A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Phase 3 Interventional Aragon Pharmaceuticals, Inc.